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Abstract 
Introduction:  
Venous thromboembolism (VTE) is a common and potentially lethal complication after total 
hip arthroplasty (THA). While low molecular weight heparin (LMWH) remains the gold 
standard antithrombotic medication after THA in Nordic countries, recent randomized trials 
have demonstrated superior efficacy in new oral anticoagulants (NOAC) such as dabigatran 
and rivaroxaban compared to LMWH. In this register study we compared established efficacy 
and safety outcomes between patients who had received LMWH and NOAC as 
thromboprophylaxis after THA.  
Method:  
Data was collected from the Swedish Hip Arthroplasty Register (SHAR), the National Patient 
Register (NPR) and the Prescribed Drug Register (PDR) to form a database from which 
32633 patients were selected. These included all primary THA procedures for patients with 
osteoarthritis. Patients who had an earlier VTE diagnosis or received a potent anticoagulant 
were excluded from the analysis. A binary logistic regression model adjusted for age, sex and 
previous antiaggregant medication was used to calculate odds ratios (OR) for VTE-incidence 
up till 3 months after surgery. 
Results:  
26881 patients received LMWH and 5752 patients were treated with NOAC. The VTE-
incidence in the LMWH group was 1.0% (n=264) and 0.4% (n=24) in the NOAC group. 
Adjusted OR for VTE was 0.42 (95% CI: 0.28-0.64, p<0.0001); deep venous thrombosis 
(DVT) 0.46 (95% CI: 0.28-0.76, p=0.002); pulmonary embolism (PE) 0.34 (95% CI:0.17-
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0.71, p=0.004); major bleeding events 0.96 (95% CI: 0.72-1.27, p=0.756); and minor 
bleeding events 0.75 (95% CI: 0.32-1.79, p=0.521) in the NOAC group. 
Conclusion:  
The incidence of VTE following THA was lower for patients with NOAC compared to those 
with LMWH as thromboprophylactic medication. There were no differences in adverse 
events including bleeding, reoperation and death. Similar, but less pronounced differences 
have been reported previously. Although, there may be residual confounding due to selection 
bias the magnitude of the difference warrants a call for change of practice. 
Abbreviations 
THA Total hip arthroplasty 
TKA Total knee arthroplasty 
VTE Venous thromboembolism 
DVT Deep venous thrombosis 
PE Pulmonary embolism 
SHAR Swedish Hip Arthroplasty Register 
PDR Prescribed Drug Register 
NPR National Patient Register 
LMWH Low molecular weight heparin 
NOAC New oral anticoagulants 
OR Odds ratio 
CI Confidence interval 
BMI Body mass index 
ASA American Society of Anesthesiologists 
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Background/Introduction 
Total hip arthroplasty (THA) is a major orthopedic procedure in practice since the 1960’s. 
THA is often referred to as one of the most successful surgical procedures in medical history. 
This has been facilitated by advancements in bioengineering technology that has increased 
both function and sustainability in hip prostheses (1). 
The original purpose of THA was solely to alleviate pain and restore mobility for patients 
with osteoarthritis (2). However, the population is demographically shifting towards a higher 
age and physically demanding activity among senior citizens is increasing. The former has 
led to a rising demand for THA procedures and the latter a need for more durable prostheses 
(1). 
Venous Thromboembolism (VTE) 
One of the most common and feared complications with THA is venous thromboembolism 
(VTE), i.e. a blood clot is formed in one of the deep veins of the leg or deep venous 
thrombosis (DVT). These clots are partly induced by the state of hypercoagulability 
associated with major joint surgery such as THA. Additionally, venous stasis and endothelial 
damage to blood vessels can attribute to DVT. 
In some instances a part of the blood clot, an embolus, loosens and travels upwards via the 
blood stream. When the embolus bypasses the liver and the heart, it can lead to a pulmonary 
embolism (PE). This is when an embolus plugs one of the pulmonary vessels, preventing the 
blocked sections of the lung from receiving blood, reducing oxygen uptake. This often 
presents clinical symptoms such as dyspnea and tachypnea and the state of hypoxia is 
potentially lethal. 
6 
 
Nonetheless, not all VTE is diagnosed as a result of clinical symptoms, e.g. DVT can be 
detected via ultrasound, fibrinogen analysis or ascending venography in patients who show 
no clinical signs of DVT such as pain and swelling of the leg. This is referred to as 
asymptomatic DVT or VTE and is much more common than symptomatic VTE, but its 
clinical significance has been disputed (3). 
Multiple studies have assessed the probability of acquiring symptomatic and asymptomatic 
VTE after THA that ranges between 0.8-2.8% the first 3 months after surgery (4-8), 1.6-2.7% 
after 6 months (7, 9) and 2.6% 1 year after surgery (4). A Danish cohort study (7) reported on 
THA patients during 1995-2010 (n=85 965) of which 0.79% had a symptomatic VTE event 
during the first 3 months postoperatively. An additional 0.29% of the patients were diagnosed 
during the remainder of the first postoperative year. This also demonstrates that VTE is most 
common in the early postoperative period. This study also reported a relative risk of 15.8 to 
suffer symptomatic VTE in the THA group compared to the general population (7). Even 
though the documented postoperative VTE incidence can vary between studies, THA 
undisputedly carries with it an increased risk of VTE. 
Without intervention asymptomatic DVT occurs for 40-60% of the THA patients and 
symptomatic VTE seems to appear for 5% (10, 11). Randomized trials between untreated 
control groups and patients who have received antithrombotic treatment have reported a 
significant decrease in both symptomless DVT and symptomatic VTE (9, 12). This 
emphasizes the importance of thromboprophylactic medication in the prevention of VTE. 
Thromboprophylaxis 
The most widely used antithrombotic treatment for patients undergoing THA in Sweden is 
low molecular weight heparin (LMWH). LMWH mediates its anticoagulant effect by binding 
to antithrombin, thus enhancing its inhibitory activity towards thrombin and the coagulation 
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factor Xa (13). The introduction of LMWH in the 1980’s was an important milestone for the 
reduction of VTE correlated to major surgery as it facilitated the administration being 
subcutaneously (s.c.), decreased side effects, required less monitoring, and enabled earlier 
discharges (14).  
That is not to say there are no difficulties with the use of LMWH’s in clinical practice. While 
outpatient administration was enabled, there is an issue with compliance as not all patients 
are comfortable with needles. This results in a high economic burden as home-care visits and 
patient education often is required (15). 
As with most interventions in health care, there are undesired side effects, 
thromboprophylaxis is not an exception. The anticoagulant effect has to be weighed against 
the risk of bleeding. This is reflected in clinical trials that measure both VTE and bleeding as 
endpoints, in the hope of finding a gold standard treatment that maximizes both efficacy and 
safety. 
Besides the evolution of thromboprophylactic agents several other steps have been taken to 
achieve this goal. Historically, the length of stay in hospitals for THA patients could exceed 
weeks (16, 17). The introduction of fast-track protocols with a multimodal approach using 
early mobilization and effective postoperative pain relief enables discharges 2-3 days after 
surgery. There are reports on reduced risk of VTE and other surgical complications after 
introduction of fast-track (17-21).  
The use of mechanical prophylaxis such as anti-embolism stockings and foot impulse devices 
has also been of aid postoperatively for patients struggling to regain mobility due to 
comorbidity (22). 
Another crucial element is the recommended treatment period. The current guidelines 
promote antithrombotic treatment for at least 10-14 days with an extended continuation up to 
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35 days (22-24), a strategy that has received support from studies financed by pharmaceutical 
companies. However, skeptics have argued that extended duration treatment forces an 
unnecessary economic burden and increases the risk of side effects for THA patients (25, 26).  
NOAC (New Oral Anticoagulants) 
However, it could be argued that the most important advance in VTE prevention was the 
introduction of new oral anticoagulants (NOAC) that happened in recent years. NOAC is 
increasingly used in clinical practice to prevent VTE. NOAC can be administered orally, 
arguably making compliance less of an obstacle (27). NOAC also seems to be a more cost-
effective alternative but this has yet to be proven significant (28).  
One of the criticisms raised towards NOAC is wound complications following surgery 
requiring prolonged wound drainage and therefore longer hospital stay. This critique has been 
directed mostly towards rivaroxaban (29, 30).  
There are currently three NOACs that have gone through phase-III-trials and are approved as 
VTE prophylaxis. The direct thrombin inhibitor dabigatran etexilate and the selective Xa 
factor inhibitors rivaroxaban and apixaban (13). 
In the ADVANCE-III double-blind study apixaban was compared with enoxaparin (a 
LMWH) after both primary and revision THA (31). 5407 patients were randomized to 
extended duration thromboprophylaxis with either 40 mg subcutaneous (sc) enoxaparin daily 
or 2.5 mg of apixaban orally twice daily for a total of 35 days. 3866 patients were used in the 
primary efficacy analysis. The approximate 30% loss of subjects happened in both study 
groups and were due to evaluation of DVT not being possible. The primary efficacy outcome 
included asymptomatic and symptomatic DVT, non-fatal PE or death from any cause during 
the treatment period. These outcomes occurred in 1.4% in the apixaban group and 3.9% in the 
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enoxaparin group, giving an absolute risk reduction of 2.5% and relative risk of 36% for 
apixaban. No significant increase in bleeding events was seen for apixaban (31). 
Dabigatran etexilate has been compared with enoxaparin after THA in two randomized 
phase-III trials, RE-NOVATE and RE-NOVATE II (32, 33). In RE-NOVATE it was 
confirmed that both 150 mg and 220 mg dose of dabigatran orally once daily was non-
inferior to enoxaparin in terms of reducing the primary efficacy outcome. This was 
determined via a non-inferiority margin for the absolute risk difference between dabigatran 
and enoxaparin. If the upper limit for the 95% confidence interval [CI] in absolute risk 
difference exceeds the non-inferiority margin of 7.7%, dabigatran would be considered 
inferior to enoxaparin. The margin of 7.7% was based on pooled data from enoxaparin vs. 
placebo trials (34-36). 
As a result of the RE-NOVATE trial in 2007 which was mainly conducted in Europe, 220 mg 
once-daily dose of dabigatran was approved for use in more than 75 countries as 
thromboprophylaxis after THA. To further establish the non-inferiority of dabigatran in a 
more diverse population the RE-NOVATE II trial was initiated. 
The RE-NOVATE II trial included 2055 patients that were randomly assigned to oral 
dabigatran 220 mg or s.c. enoxaparin once daily. 1577 (76.7%) patients were eligible for 
primary efficacy analysis. Similar to the ADVANCE-III trial for apixaban, the exclusion of 
almost 500 patients for the primary efficacy analysis was mostly due to lack of or non-
interpretable venographic data.  
As in the RE-NOVATE trial, no significant difference was seen between dabigatran and 
enoxaparin in terms of reducing primary efficacy events. The absolute risk difference was 
1.1% (p=0.43). However, as the 95% CI did not exceed the 7.7% margin, dabigatran was 
again shown to be non-inferior to enoxaparin, without any significant rise in bleeding (33). 
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Rivaroxaban has been studied in two phase-III trials (RECORD-I and RECORD-II) and 
recently a phase IV-trial (XAMOS) (37-39). 
In RECORD-I 4541 THA patients were randomized to extended duration 
thromboprophylaxis with either 40 mg s.c. enoxaparin or 10 mg of oral rivaroxaban once 
daily plus a placebo tablet or injection. In RECORD-II 2509 patients scheduled for THA 
were randomly split into two groups, one receiving extended duration treatment with 10 mg 
once-daily oral rivaroxaban and the other short-term treatment with 40 mg of s.c. enoxaparin 
(10-14 days). Primary efficacy analyses in both studies were performed in a modified 
intention-to-treat groups which consisted of all patients who had undergone surgery, received 
at least one dose of study medication and had adequate assessment of thromboembolism, 
69% of the patients who had been randomized (in both RECORD-I and RECORD-II). 
Similar to the RE-NOVATE trials the aim of the RECORD-I trial was primarily to ascertain 
the non-inferiority of rivaroxaban compared to enoxaparin. Therefore a non-inferiority 
analysis for primary efficacy outcome preceded the superiority analysis on the modified 
intention-to-treat cohort. RECORD-I found an absolute risk reduction in primary efficacy 
outcome of 2.6% (p<0.001) and relative risk reduction of 70% for rivaroxaban in the 
modified intention-to-treat population. 
The primary goal of RECORD-II was to determine if extended duration treatment with 
rivaroxaban was superior to short-duration treatment with enoxaparin. RECORD-II reported 
an absolute risk reduction of 7.3% (p<0.001) for primary efficacy outcome for extended-
duration rivaroxaban in the modified intention-to-treat cohort. No significant elevation in risk 
of bleeding was seen in the rivaroxaban group. 
All the above mentioned studies use strict inclusion and exclusion criteria that make it 
difficult to determine if the results are applicable to routine clinical practice. Phase-IV studies 
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provide a real-world setting that can further establish the superior efficacy of NOAC 
compared to LMWH. It was for this reason that the XAMOS study was launched (39). 
17701 patients who underwent either THA or TKA were enrolled in the XAMOS study and 
multiple clinical outcomes such as thromboembolism, bleeding, wound complications and 
death were recorded. Patients were assigned to receive rivaroxaban or standard-of-care (of 
which 81.7% received LMWHs and 5.5% received dabigatran). The incidence of 
symptomatic VTE was 0.65 % in the rivaroxaban group and 1.02 % in the standard-of-care 
group with an odds ratio [OR] of 0.63 (95% CI, 0.45-0.89) for rivaroxaban. No significant 
difference was found for any bleeding or adverse events. 
The XAMOS and preceding phase III studies have given a solid foundation for suggesting 
NOAC as an alternative to LMWH where daily injections are an inconvenience. Yet, among 
critics there is still skepticism for offering NOAC instead of LMWH due to believed risk of 
bleeding and lack on long-term safety data (40). 
A meta-analysis assessing a total of 16 randomized trials for NOAC in major joint surgery 
found that NOAC had similar efficacy and safety to LMWH but higher efficacy and was 
often associated with a rise in bleeding events. Compared with enoxaparin, the incidence of 
symptomatic VTE was lower with rivaroxaban (relative risk 0.48, 95% CI 0.31-0.75), but did 
not differ significantly with dabigatran (0.71, 0.23 to 2.12) and apixaban (0.82, 0.41 to 1.64). 
Using clinically relevant bleeding as a safety outcome they found that when compared to 
enoxaparin, the risk was higher with rivaroxaban (1.25, 1.05 to 1.49) and similar with 
dabigatran (1.12, 0.94 to 1.35) and lower with apixaban (0.82, 0.69 to 0.98) (41).  
The Swedish Hip Arthroplasty Register (SHAR) 
The SHAR was founded in 1979 as a national quality register to evaluate and provide 
guidelines for THA procedures. The clinical data from SHAR is used for multiple purposes: 
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The assessment of health care institutions and their activities, the continuous encouragement 
for clinical improvement and clinical research (42).  
The SHAR also has an important role in post-market surveillance of implants. This has for 
instance led to discontinued use of some implants that have not performed well according to 
standards. Sweden has one of the lowest THA revision rates globally which has been largely 
credited to the activity of SHAR (43). 
The information relayed to the SHAR is reliant upon the treating units that are supplying it. 
Therefore, the register examines the data quality and the completeness of the data (number of 
reported hip replacements/number of performed hip replacements) on an annual basis. The 
data completeness has been measured at 98-99% despite the participation from health care 
institutions not being mandatory (42). 
Furthermore, SHAR documents approximately 16500 THA in their annual report for 2015 
(44). With such a large number of patients undergoing THA the SHAR has access to data 
from hundreds of thousands of THA procedures, offering enough statistical power to permit 
the study of rare complications such as VTE. 
Still, what SHAR can evaluate via medical research is limited to the data that is collected. 
Incidence of VTE is regrettably not included in the database. However, by interlinking SHAR 
with other registers researchers are able to perform analysis on variables from multiple 
databases. This is facilitated by the 10-digit personal identity number (PIN) maintained by the 
Swedish Tax Agency. 
With access to data from the NPR and the Prescribed Drug Register (PDR), both governed by 
the National Board of Health and Welfare, we can assess the occurrence of VTE and adverse 
events after THA after controlling for the prescribed thromboprophylaxis. The cross-linking 
of these registers and the vast amount of data collected offers a unique opportunity to 
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extensively evaluate the effectivity and safety of LMWH and NOAC after THA. We hope 
this study will offer robust evidence for the ongoing debate on thromboprophylaxis and 
potentially be used as a springboard for change in Nordic health care policy. 
Objectives 
The aim was to explore differences in VTE incidence after THA for patients treated with 
LMWH or NOAC. Furthermore, we assessed the association between medication and adverse 
events such as bleeding, reoperation and mortality. 
Methods 
Data was previously collected from the SHAR, the NPR and the PDR (both governed by the 
National Board of Health and Welfare) to form a cross-linked register database in another 
study (43). A formal request of access was filed via the SHAR to make the data available to 
the author. No additional data collection was necessary.  
A cohort consisting of 32 663 patients was selected from the interlinked registers. The 
selection process included multiple steps (Figure 1). We included all primary THA 
procedures between 2008 and 2012 in patients suffering from osteoarthritis. Patients with 
high risk of developing VTE including those with other diagnoses than osteoarthritis (e.g 
tumors, congenital disorders or hip fractures), previous VTE diagnosis or a prescription of a 
potent anticoagulant (warfarin, LMWH or NOAC) 6 months preoperatively were excluded. 
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Figure 1. Study group selection flow chart 
 
Exposure was defined as thromboprophylaxis after THA. Patients who had received LMWH 
or NOAC were divided into two separate study cohorts for statistical analysis. In order to be 
included in the analysis exposure had to precede all potential outcomes and the prescription 
had to have been purchased within 10 days of the index operation (Figure 2).  
Exposure data was selected from ATC-codes reported in the register from the National Board 
of Health and Welfare. Three ATC-codes for LMWH (B01AB04, B01AB05, B01AB10) 
corresponding to dalteparin (Fragmin), enoxaparin (Klexane) and tinzaparin (Innohep) were 
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included. NOAC consisted of two ATC-codes (B01AE07, B01AF01) standing for dabigatran 
etexilate (Pradaxa) and rivaroxaban (Xarelto). 
Occurrences of VTE, DVT and PE up till 3 months postoperatively were our primary 
endpoints. Adverse events were also measured in the same time frame as secondary 
outcomes. These included major bleeding, minor bleeding, reoperation and mortality. 
Mortality and reoperations are reported for every THA in the SHAR and were directly 
applicable for analysis. 
Figure 2. Time axis used in study design 
  
However, VTE, DVT, PE, major and minor bleeding were all diagnostic outcomes that 
required specific definitions before analysis could be performed. Since this data was not 
available in SHAR we used ICD-10 codes reported in the NPR to define these outcomes. 
A search with the keywords “thrombosis”, “bleeding” and “haematoma” was performed in an 
ICD-10 database. Specific ICD-10 codes corresponding to every outcome were selected by 
the research group. See appendix for the ICD-10 list for each of these outcomes. The 
separation between what was considered major and minor bleeding events was based on a 
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research article that had examined the definition of bleeding as a secondary outcome in 
clinical trials reporting on THA (45).  
Originally the study population included patients from 2006-2012. This period was later 
changed to 2008-2012 for several reasons. Firstly, there was only a single patient registered 
for 2007 after the data had bypassed our selection criteria, whereas, the other years the 
number of patients exceeded at least 3500 per year. Secondly, BMI had not been recorded in 
SHAR earlier than 2008. Finally, no patients in the NOAC group were registered prior to 
2008. 
Setting the time frame for purchasing prescriptions was based on the distribution of data from 
the interlinking registers. A plotted histogram over the days between index operation and 
purchased prescriptions revealed that the majority of patients had already bought it after 3-5 
days. From this we concluded that setting a margin of 10 days postoperatively would not 
exclude a large portion of THA operations. It would also limit the inclusion of high-risk 
patients, excluding those who were unable to get an early discharge due to comorbidity. 
Statistical methods 
The statistical analysis was performed using IBM SPSS software, version 21. The data was 
analyzed in a binary logistic regression model to determine the odds ratio [OR] with a 95% 
confidence interval. A p-value below 0.05 was considered statistically significant. 
Each of the observed outcomes was used as the dependent variable in a binary logistic 
regression. We calculated the OR both in a univariate unadjusted and a multivariate adjusted 
analysis with sex, age and previous antiaggregant medication as confounders. 
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Ethics 
This study was approved by a Regional Ethical Review Board in Gothenburg (entry number 
271-14).  
This was a register study that didn’t require any contact with the patient. The data in SPSS 
could only be accessed via a remote desktop server called SODA (Secure Online Data-
Access) requiring dual step identification. The data could not be transferred or copied from 
SODA and hence all the analyses were done via this network. The patients were 
anonymously listed in the database and the key to unlock the identity of the patient was not 
available to the research team. We determine the possibility of reidentifying individuals by 
anyone in the research team to be close to non-existent. 
Furthermore, SHAR is a well-established national register with a research record of over 40 
years. Without the use of SHAR, it would prove very difficult to gather the large number of 
patients required for studying the primary endpoints described in this paper. Considering the 
effort of clinicians who report patient data to the SHAR and the National Board of Health and 
Welfare we are as researchers obligated to use that information to continuously evaluate 
current treatment policies and find areas where improvement is achievable.  
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Table 1. Demographic and clinical characteristics of the study population 
*standard deviation 
 
Results 
The distribution of gender was equal across both groups with an expected domination of 
women. (Table 1).  
 NOAC LMWH p-value 
N 5752 26881  
Gender = female - n (%) 3329 (57.9) 15339 (57.1) 0.264 
Age - mean (sd*) 68.19 (9.97) 67.75 (9.95) 0.002 
BMI (kg/m
2
) - mean (sd) 27.45 (4.45) 27.28 (5.29) 0.031 
ASA - n (%)   <0.001 
   Healthy (I) 1605 (29.2) 6926 (26.5)  
   Mild (II) 3280 (59.7) 15913 (60.9)  
   Severe (III) 598 (10.9) 3228 (12.3)  
   Life-threatening (IV) 7 (0.1) 70 (0.3)  
   Moribund (V) 0 (0.0) 1 (0.0)  
Elixhauser - mean (sd) 0.76 (0.93) 0.63 (0.93) <0.001 
Education - n (%)   <0.001 
   Low 1929 (33.6) 8616 (32.1)  
   Middle 2447 (42.6) 11113 (41.4)  
   High 1372 (23.9) 7120 (26.5)  
Civil state – n (%)   0.205 
   Couple 3260 (56.7) 15254 (56.8)  
   Single 1622 (28.2) 7774 (29.0)  
   Widow 866 (15.1) 3822 (14.2)  
Fixation – n (%)   <0.001 
   Cemented 4142 (72.1) 17123 (64.0)  
   Uncemented 888 (15.5) 4371 (16.3)  
   Hybrid 93 (1.6) 210 (0.8)  
   Reversed hybrid 609 (10.6) 4607 (17.2)  
   Resurfacing 13 (0.2) 463 (1.7)  
 
Education showed a trend towards a higher standard in the LMWH group. Two measures for 
comorbidity, the American Society of Anesthesiologists (ASA) classification and Elixhauser 
comorbidity index were included, where a higher value indicates further comorbidity. 
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Interestingly, the ASA classification, in contrast with the Elixhauser comorbidity index, 
shows a slightly lower comorbidity in the NOAC population. 29.2% in the NOAC group 
were classified as ASA I, compared to 26.5% in the LMWH group whilst the mean 
Elixhauser comorbidity index was almost 21% greater among NOAC patients. Data on 
prosthesis fixation showed that there was a higher tendency towards cementation in the 
NOAC group and lower use of reversed hybrid fixation. 
VTE events occurred in 264 of 26881 patients (1.0%) in the LMWH group and 24 of 5752 
patients (0.4%) in the NOAC group. The adjusted OR in the NOAC group was 0.42 (95% 
confidence interval [CI], 0.28-0.64; p<0.0001). This analysis showed that NOAC is superior 
compared to LMWH in terms of effectiveness.  
 
 
DVT was diagnosed in 170 of 26881 patients (0.6%) in the LMWH group and 17 of 5752 
patients (0.3%) in the NOAC group. Adjusted OR in the NOAC group was 0.46 (95% CI, 
Figure 3. The forest plot presents crude (blue) and adjusted (red) odds ratios for  
NOAC with LMWH as reference.  
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0.28-0.76; p=0.002). PE was identified in 108 of 26881 patients (0.4%) in the LMWH group 
and 8 of 5752 patients (0.1%) in the NOAC group. Adjusted OR in the NOAC group was 
0.34 (95% CI, 0.17-0.71; p=0.004).  
Major bleeding events occurred in 281 of 26881 patients (1.0%) in the LMWH group and 58 
of 5752 (1.0%) in the NOAC group. Adjusted OR in the NOAC group was 0.96 (95% CI, 
0.72-1.27; p=0.756). 
Minor bleeding events were suffered by 37 of 26881 patients (0.1%) in the LMWH group and 
6 of 5752 (0.1%) in the NOAC group with an adjusted OR of 0.75 in the NOAC group (95% 
CI, 0.32-1.79; p=0,521) 
Death during follow-up was confirmed in 38 of 26881 patients (0.1%) in the LMWH group 
and 6 of 5752 patients (0.1%) in the NOAC group. Adjusted OR was 0.72 in the NOAC 
group (95% CI, 0.30-1.70; p=0.455).  
A total of 202 patients underwent reoperation. 162 patients were from the LMWH group 
(0.6%) and 40 patients were from the NOAC group (0.7%). Adjusted OR in the NOAC group 
was 1.16 (95% CI, 0.82-1.64; p=0.412). 
Discussion 
This explorative study was conducted in order to describe any potential significant 
differences in VTE incidence and adverse events between NOAC and LMWH after primary 
THA in patients suffering from osteoarthritis. 
The results reveal a significantly lower occurrence of VTE in patients who were given NOAC 
compared to LMWH. Risk of developing VTE, DVT and PE remained significantly lower in 
the NOAC group after adjusting for sex, age and previous antiaggregant medication. 
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Furthermore, the analysis did not show any significant difference for reoperations, bleeding 
or mortality between NOAC and LMWH.  
Comparison to similar studies 
Our findings are in accordance with those found in phase III clinical trials for NOAC and the 
XAMOS Phase IV-study comparing rivaroxaban (NOAC) with enoxaparin (LMWH) (31-33, 
37-39). However, important to note is that these trials did not use the same primary endpoints 
as this study and therefore are not directly comparable. 
To the best of our knowledge, these calculations affirm a greater superiority with NOAC than 
previously published in the literature. As a result of this, we suspected that a fraction of the 
288 patients that suffered VTE could have been receiving treatment for an unregistered VTE 
instead of prophylaxis. Due to LMWH being the most commonly prescribed medication for 
VTE in most Swedish hospitals this could have resulted in patients being falsely classified as 
LMWH.  
Using the data from the PDR, we confirmed that all (except three) patients belonging to the 
LMWH group had received a prophylaxis dose of LMWH preceding VTE treatment. It is still 
possible that these patients had been offered prophylaxis but not via prescription. Regardless 
if these three cases were categorized correctly or not, we assume that this limited number 
does not have any impact on our results. 
There is constantly a risk of confounding bias caused by differences in demographic and 
clinical characteristics between patient cohorts. We found a significantly higher Elixhauser 
comorbidity index in the NOAC group. This could arguably have influenced our results, yet 
the effect would be a higher incidence of complications in the NOAC population, including 
VTE. The higher comorbidity in the NOAC cohort likely was not a source of confounding for 
superior effectiveness with NOAC. 
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Moreover, there was a tendency towards more cemented fixation in the NOAC group. Studies 
have reported cementation as a potential risk factor for VTE (46, 47). Assuming that 
cementation increases the risk for VTE, the same principle as above can be applied, since it 
would not contribute to decreasing the amount of VTE events in the NOAC group.  
Additionally, the symptomatic VTE-incidence recorded in our study is generally lower 
compared to those found in randomized trials. The RECORD-I trial reported a VTE-
incidence of 1.1% in the rivaroxaban group and 3.7% in the enoxaparin group despite a 
follow-up of 36 days, almost three times shorter than our follow-up (37). The XAMOS study 
documented a 3-month-VTE-incidence at 0.89% for rivaroxaban and 1.35% for standard-of-
care (82% enoxaparin) (39). 
One potential explanation is the rigid selection criteria in this study. Only primary THA 
procedures for osteoarthritic patients that had not suffered VTE in the last 5 years were 
included. In comparison, the XAMOS study included all patients aged above 18 who were to 
undergo THA, TKA or hip fracture surgery where rivaroxaban was indicated (39).  
Another reason for low VTE-incidence could be underreporting in the NPR. However, this 
would affect the registration of VTE events for both NOAC and LMWH, hence our results 
are still comparable. 
Strengths and weaknesses of study 
Surprisingly, there was a large portion of the patient cohort (n=16899) that did not contain 
any data from the PDR. It is very unlikely that all of these patients were not offered 
antithrombotic medicine. One possible explanation is that certain hospitals may have a 
specific treatment regimen that does not include prescriptions for LMWH or NOAC during 
discharge. For example, one might allow patients to take LMWH injections home with them 
bypassing the pharmacy or only offer antithrombotic treatment during hospitalization. 
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Regardless, due to the lack of information on this patient group it is impossible to draw any 
conclusion in regards to our measured outcomes, therefore we excluded this group from the 
analysis. 
We performed an exclusion analysis on these patients to determine if their removal from the 
study group affected our results. We found that the VTE-incidence for the patients that had 
been excluded was similar to the study group (0.4 %). See appendix. 
One of the selection criteria for the study group was that the patient needed to have purchased 
their prescription within 10 days of the index operation. This was intended to exclude highly 
comorbid patients but could have also unintentionally excluded a portion of NOAC patients 
that were forced to remain in the hospital longer due to wound drainage.  
Our study only included patients who underwent primary THA and had been diagnosed with 
osteoarthritis. Yet, there are other large patient groups such as hip fractures, tumors etc. that 
undergo hip surgery. Despite the magnitude of the difference in effectiveness recorded, it is 
important to further investigate safety risks associated with NOAC that was not captured 
within the framework of this study. The optimal way of pursuing this objective is via phase-
IV clinical studies such as the XAMOS study for rivaroxaban (39).  
Nonetheless, the magnitude of the difference between the NOAC and LMWH population in 
terms of effectiveness challenges the traditional mindset of LMWH being the gold standard 
thromboprophylactic medication after THA. Future studies will have to examine this 
relationship further in other patient cohorts going through THA. 
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Populärvetenskaplig sammanfattning (In 
Swedish) 
I Sverige utförs fler än tiotusen höftprotesoperationer varje år och så stora kirurgiska ingrepp 
medför alltid en risk för patienten att drabbas av komplikationer efter operationen. En av de 
vanligaste komplikationerna är uppkomsten av blodproppar i benen som kan föras vidare via 
blodbanan och ge upphov till en livshotande propp i lungan. 
För att förhindra detta behandlas samtliga höftprotespatienter med proppförebyggande 
läkemedel under en till flera veckor efter operation. Behandlingen ges vanligen genom 
sprutor med lågmolekylärt heparin (LMH) men de senaste åren används även s.k. NOAK-
tabletter. 
I denna studie har vi jämfört förekomsten av proppar upp till tre månader efter operationen 
hos patienter som tagit LMH och NOAK. Studien baseras på data från svenska 
höftprotesregistret för tidsperioden 2008-2012 vilka i en tidigare studie samkörts med 
läkemedelsregistret och patientregistret. 30000 patienter behandlades med LMH och 5700 
patienter med NOAK. Förekomsten av proppar i LMH-gruppen var 1.0% och i NOAK-
gruppen 0.4%. Vi fann ca 60% lägre risk att få proppar hos NOAK-gruppen och vi fann ingen 
märkbar skillnad vad avser blödningar, omoperationer eller dödsfall mellan grupperna.Våra 
resultat överensstämmer med tidigare forskning, men nu för första gången med en större 
grupp patienter. 
Således har denna studie bättre än tidigare studier klargjort risken för proppar och andra 
biverkningar efter en höftprotesoperation. Dock krävs ytterligare forskning för att också 
studera andra eventuella risker med användandet av NOAK vilka inte inkluderats i denna 
studie. 
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Våra resultat talar dock starkt för den enklare och för patienten mer skonsamma NOAK 
metoden och emot den traditionella LMH metoden som den effektivaste behandlingen mot 
proppbildning efter en höftprotesoperation. 
Acknowledgements 
Szilard Nemes PhD – For providing irreplaceable aid with the statistical analysis despite his 
workload. 
Maziar Mohaddes MD, PhD – For laying the groundwork for this project and his mentorship. 
Ola Rolfson MD, PhD – For his invaluable mentorship. 
Appendix 
Table 2. ICD-10 codes used to define outcome. 
 
 
 
 
 
 
 
 
 
  
VTE DVT PE Major bleeding Minor bleeding 
I82.8  I81.9  I26.0  R04.1  K27.0  H43.1  I61.4  J38.3J K625 
I82.2  I82.9  I26.9  R04.8  K27.2  H45.0*  I61.5  O90.2 L608J 
I82.3  I82.8   R04.9  K27.4  I60.0  I61.6  O71.7 N421 
I26.0  I82.2   R23.3  K27.6  I60.1  I61.8  T14.5 N501A 
I26.9  I82.3   R23.3W  K28.0  I60.2  I61.9  N89.7 N922 
I81.9    R58.9  K28.2  I60.3  I62.0  N83.6 N923 
I82.9    S06.4  K28.4  I60.4  I62.1  N83.7 N924 
   S06.40  K28.6  I60.5  I62.9  AAD10 N930 
   S06.41  D62.9  I60.6  I85.0  AAD05 N938 
   T81.0  H31.3  I60.7  I98.3*  AAB30 N939 
   K92.2  H35.6  I60.8  K22.6  AAD15 N950 
   K25.6  H35.6A  I60.9  K25.0  AAD00 N950A 
   K26.0  H35.6B  I61.0  K25.2  ABB40 N950B 
   K26.2  H35.6C  I61.1  K25.4 TQX05  N950W 
   K26.4  H35.6W  I61.2   H113 N950X 
   K26.6  H35.6X  I61.3   H922 T140A 
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Table 3. Treating units with missing data from Prescribed Drug Register 
Unit Missing 
(n) 
Existing 
(n) 
Total 
(n) 
Missing 
(%) 
VTE 
(n) 
DVT 
(n) 
PE 
(n) 
Aleris Specialistvård Elisabethsjukhuset 4 309 313 1% 0 0 0 
Aleris Specialistvård Motala 1028 68 1096 94% 8 5 3 
Aleris Specialistvård Nacka 8 406 414 2% 0 0 0 
Aleris Specialistvård Sabbatsberg 4 456 460 1% 0 0 0 
Alingsås 152 648 800 19% 0 0 0 
Art Clinic Jönköping 1 6 7 14% 0 0 0 
Arvika 5 644 649 1% 0 0 0 
Bollnäs 12 932 944 1% 0 0 0 
Borås 28 458 486 6% 0 0 0 
Capio Movement 750 115 865 87% 0 0 0 
Capio Ortopediska Huset 25 1560 1585 2% 1 0 1 
Capio S:t Göran 166 1275 1441 12% 2 1 1 
Carlanderska 11 388 399 3% 0 0 0 
Danderyd 68 942 1010 7% 1 1 0 
Eksjö 696 84 780 89% 5 2 3 
Enköping 31 1009 1040 3% 0 0 0 
Eskilstuna 117 147 264 44% 1 0 1 
Falköping 11 497 508 2% 0 0 0 
Falun 154 1051 1205 13% 0 0 0 
Frölunda Specialistsjukhus 54 293 347 16% 0 0 0 
Gällivare 11 295 306 4% 0 0 0 
Gävle 58 378 436 13% 1 0 1 
Halmstad 317 408 725 44% 0 0 0 
Helsingborg 75 63 138 54% 0 0 0 
Hudiksvall 2 366 368 1% 0 0 0 
Hässleholm-Kristianstad 2599 368 2967 88% 12 4 8 
Jönköping 576 132 708 81% 3 1 2 
Kalmar 478 56 534 90% 0 0 0 
Karlshamn 12 792 804 1% 0 0 0 
Karlskoga 4 494 498 1% 0 0 0 
Karlskrona 2 26 28 7% 0 0 0 
Karlstad 15 594 609 2% 0 0 0 
Karolinska/Huddinge 48 647 695 7% 1 0 1 
Karolinska/Solna 62 474 536 12% 1 0 1 
Katrineholm 416 564 980 42% 1 0 1 
Kungälv 94 535 629 15% 0 0 0 
Köping 44 10 54 81% 0 0 0 
Lidköping 8 534 542 1% 0 0 0 
Lindesberg 13 720 733 2% 0 0 0 
Linköping 125 23 148 84% 0 0 0 
Ljungby 533 56 589 90% 3 2 1 
Lycksele 575 605 1180 49% 3 1 2 
Mora 40 719 759 5% 1 1 0 
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Motala 447 47 494 90% 1 1 0 
Norrköping 689 67 756 91% 1 0 1 
Norrtälje 19 349 368 5% 0 0 0 
Nyköping 512 44 556 92% 0 0 0 
Ortho Center IFK-kliniken 2 42 44 5% 0 0 0 
Oskarshamn 780 57 837 93% 1 0 1 
Piteå 14 1437 1451 1% 0 0 0 
Skellefteå 10 279 289 3% 1 0 1 
Skene 18 381 399 5% 0 0 0 
Skövde 3 468 471 1% 0 0 0 
Sollefteå 12 438 450 3% 1 0 1 
Sophiahemmet 16 647 663 2% 0 0 0 
Spenshult 50 365 415 12% 0 0 0 
SU/Mölndal 42 851 893 5% 2 2 0 
SU/Östra 12 98 110 11% 0 0 0 
Sunderby 2 25 27 7% 0 0 0 
Sundsvall 163 461 624 26% 0 0 0 
SUS/Lund 72 16 88 82% 0 0 0 
SUS/Malmö 72 25 97 74% 0 0 0 
Södersjukhuset 80 1009 1089 7% 1 1 0 
Södertälje 38 375 413 9% 1 0 1 
Torsby 6 371 377 2% 0 0 0 
Trelleborg 1979 386 2365 84% 8 6 3 
Uddevalla 176 910 1086 16% 2 0 2 
Umeå 27 208 235 11% 0 0 0 
Uppsala 176 487 663 27% 1 1 0 
Varberg 88 707 795 11% 0 0 0 
Visby 102 318 420 24% 1 0 1 
Värnamo 446 70 516 86% 2 1 1 
Västervik 365 32 397 92% 2 1 1 
Västerås 124 1031 1155 11% 1 0 1 
Växjö 393 45 438 90% 1 0 1 
Ängelholm 34 408 442 8% 0 0 0 
Örebro 458 66 524 87% 1 0 1 
Örnsköldsvik 4 610 614 1% 0 0 0 
Östersund 32 791 823 4% 1 1 0 
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